King george’s medical university, chowk, lucknow u.p. india electricity projects for grade 7

#########

Sealed tenders under two bid system are hereby invited from authorized distributor/Dealer or registered contractor of Electric department KGMU for supply of electrical goods. The tender shall be opened on 20-10-2018 timing 4.00 PM at Electric Department KGMU. The details of the tender document can be viewed at university website www.kgmcindia.edu & www.KGMU.org and other terms and condition regarding the tender and supply can be viewed in the office of electric department during any working days.

Online E-Tenders under two Bid system (Technical & Financial) are invited on Turn-Key basis for the MANAGEMENT OF Private Ward Obst. & Gynaecology (Queen Mary Hospital) King Georges Medical University, U.P, Lucknow. from the reputed agencies, on the terms & condition as per tender document.The details of the Tender will be available on e-portal website http://etender.up.nic.in

Online e-bids are invited on two e-bids systems latest by 16/10/2018 at 05:00 PM for the supply of Non Rate Contract General Medicines, Cancer Drugs, Surgical Consumables and DPCO items from local Chemists/Firms situated within a radius of 10 km of Trauma Centre, KGMU, Lucknow at KGMU, HRF. o goshi technique The details of the tender can be viewed at www.kgmu.org. Tender will be available on e-portal https://etender.up.nic.in.

Online e-bids are invited on two e-bid Systems for the MANAGEMENT OF DIFFERENT PARKING SLOTS AT King George’s Medical University, U.P, Lucknow. from the reputed agencies(Joint Ventures/consortiums not eligible) on the terms & condition as per tender document. Only Manual Bids shall not be accepted. The details of the Tender will be available on e-portal website http://etender.up.nic.in.

Sealed tenders under two bid system are hereby invited from authorised service agency/ Dealer of AC manufacturers and the registered electrical contractors of KGMU for CAMC of air conditioners. The tender shall be opened on 12-06-2018 timing 4.00 PM at Electric Department KGMU. gas pains 6 weeks pregnant The details of the tender document can be viewed at university website www.kgmcindia.edu & www.KGMU.org and other terms and condition regarding the tender and work can be seen in the office of electric department during any working days.

Sealed tenders under two bid system are hereby invited from the registered electrical contractors of Govt. deptt/ KGMU for the execution of (A.) Providing of new wiring in E.N.T. Department. (B.) Repairing of 1000 KVA Transformer (C.) Repairing of 630 KVA Transformer. electricity production in chad The tender shall be opened on 22-05-2018 timing 4.00 PM at Electric Department KGMU.

A. In the trial by Mok et al., the safety profile for osimertinib was consistent with that reported previously and differed from that in the platinum-pemetrexed group. Overall, adverse events tended to be more severe in the platinum-pemetrexed group, despite the longer treatment duration with osimertinib. In the osimertinib group, the most commonly reported adverse events were diarrhea (in 113 patients [41%]), rash (in 94 [34%]), dry skin (in 65 [23%]), and paronychia (in 61 [22%]). Osimertinib was associated with a lower rate of adverse events leading to permanent discontinuation than was platinum-pemetrexed (in 19 patients [7%] and 14 patients [10%], respectively). la gasolina daddy yankee mp3 February 21, 2017

A. In the trial by Mok et al., the authors found that patients with T790M-positive advanced non-small-cell lung cancer who received osimertinib had better response rates and a longer duration of progression-free survival than did those receiving platinum therapy plus pemetrexed after first-line EGFR-TKI therapy. The progression-free survival benefit with osimertinib was observed across all predefined subgroups, with hazard ratios of less than 0.50, including in patients with asymptomatic central nervous system metastases. In five prespecified measures of patient-reported symptoms, osimertinib had better results than platinum-pemetrexed. 76 gas card payment February 21, 2017

Among patients with advanced non-small-cell lung cancer with a mutant EGFR, EGFR tyrosine kinase inhibitors (TKIs) are the standard first-line therapy. Despite high tumor response rates with first-line EGFR-TKIs, disease progresses in a majority of patients after 9 to 13 months of treatment. What percentage of patients with advanced non–small-cell lung cancer and a mutant EGFR develop a T790M mutation?

At the time of progression, about 60% of patients (regardless of race or ethnic background) are found to have a p.Thr790Met point mutation (T790M) in the gene encoding EGFR. The presence of the T790M variant reduces binding of first-generation or second-generation EGFR-TKIs to the ATP-binding pocket of EGFR, thereby reducing EGFR-TKI-mediated inhibition of downstream signaling and potentially leading to disease progression.

Osimertinib is an oral, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR and T790M resistance mutations in patients with non-small-cell lung cancer. On the basis of results of phase 1 and phase 2 studies, the Food and Drug Administration approved osimertinib under the Breakthrough Therapy Designation Program. arkansas gas and oil commission Mok et al. conducted a confirmatory, randomized, open-label, international, phase 3 trial (AURA 3) to show the superiority of osimertinib over platinum therapy plus pemetrexed (followed by optional pemetrexed maintenance) as standard of care for patients with centrally confirmed T790M-positive advanced non-small-cell lung cancer after first-line EGFR-TKI therapy. February 17, 2017